InMed-Mentari Merger Secures US$290M, Funds Migraine Programs Through 2028
INM•InMed will merge with Mentari Therapeutics in an all-stock deal valuing the combined company at US$421.4 million, with InMed shareholders holding about 1.51%. A US$290 million private placement will fund MT-001 anti-PACAP and MT-002 anti-CGRP/PACAP bispecific migraine programs through 2028, with first-in-human filings planned mid-2026 and Q1 2027.
1. Merger Terms and Structure
InMed and Mentari Therapeutics have entered a definitive all-stock merger agreement under which the combined company will be named Mentari Therapeutics and trade on the Nasdaq Capital Market under a new ticker. The transaction will give pre-merger InMed shareholders approximately 1.51% of a company valued at about US$421.4 million on a pro forma basis.
2. Mentari Migraine Pipeline
Mentari’s lead programs include MT-001, an anti-PACAP monoclonal antibody with Phase 2a proof-of-concept data expected in 2028, and MT-002, a first-in-class anti-CGRP/PACAP bispecific antibody with Phase 1 healthy volunteer data due in Q1 2027. These candidates target complementary migraine pathways to address suboptimal responses in two-thirds of patients on existing therapies.
3. Financing and Ownership
A concurrent oversubscribed US$290 million private placement led by major health-focused investors will fully fund operations through 2028. Financing support, combined with public-market infrastructure, positions the merged company to advance its migraine portfolio and execute rapid development timelines.
4. Closing Timeline and Conditions
The merger is expected to close in the second half of 2026, subject to shareholder approvals, effectiveness of a registration statement, and other customary conditions. Upon closing, the combined entity will benefit from a strengthened balance sheet and clear regulatory path for its lead migraine programs.
